Rabbit anti Human Factor V

Precipitation assays. In immunoelectrophoresis in agarose-plates use 2 ul human plasma or equivalent against 120 ul antiserum. In double radial immunodiffusion use a rosette arrangement with 10 ul antiserum in 3 mm diameter center well and 2 ul plasma samples (neat and serially diluted) in 2 mm diameter peripheral wells. In electroimmunodiffusion the antiserum concentration required in the gel is normally between 1 and 2%. Measured by quantitative precipitin analysis. The amount of factor V precipitated by 1 ml antiserum is between 8 and 12 U. One Unit of Factor V is defined as the amount of factor V present in 1 ml normal plasma. On the average this corresponds to 20 ug.

The defined antibody reactivity is restricted to Factor V, its activated form (Fva) and degradation products. In immunoelectrophoresis, bidimensional electrophoresis, and double radial immunodiffusion (Ouchterlony) against plasma, a single precipitin line is obtained which shows a reaction of identity with the precipitated purified Factor V. No precipitation is obtained with Factor V-depleted plasma and serum. In precipitating techniques as electroimmunodiffusion, immunoelectrophoresis, single and double radial immunodiffusion (Mancini, Ouchterlony), bidimensional electrophoresis and neutralization assay. The presence of non-precipitating antibodies has not been assayed. If used in more sensitive test procedures or as catching or detection antibody in solid phase immunoassays specificity controls should always be include. Plasma samples and all assay components must contain EDTA to stabilize the proteins.

This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. This product contains sodium azide. To prevent formation of toxic vapors, do not mix with strong acidic solutions. To prevent formation of potentially explosive metallic azides in metal plumbing, always wash into drain with copious quantities of water. This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.

Delipidated, heat inactivated, lyophilized, stable whole serum, dialyzed against glycine buffer. Sodium azide 1 mg/ml Total protein and IgG concentrations in the antiserum are comparable to those of pooled normal rabbit serum. No foreign proteins added.

Delipidated, heat inactivated, lyophilized, stable whole serum, dialyzed against glycine buffer. Sodium azide 1 mg/ml Total protein and IgG concentrations in the antiserum are comparable to those of pooled normal rabbit serum. No foreign proteins added. Reconstitute the lyophilized antiserum by adding 1 ml sterile distilled water.

Plasma factor V is a relatively labile glycoprotein (MW 350,000) which is essential for normal clotting and haemostasis. It is synthesized in hepatocytes and reticuloendothelial cells in the liver. Factor V is present in platelet alpha-granules but not on the surface of the intact platelet. It is released following platelet aggregation and its coagulant activity is distinguishable from plasma factor V. Thrombin activates Factor V to FVa by proteolysis resulting in the release of several polypeptides with molecular weight of 70,000 to 150,000. After clotting he protein is no longer detectable in the serum. FVa binds to receptor sites in the platelet membrane which protects Fva from the action of inhibitors (e.g. protein C). The concentration of factor V in adult plasma is 1-3 ug/ml. Newborn infants have similar levels. Factor V deficiency is associated with severe haemorrhagic disorder. Congenital deficiency with an autosomal bleeding is relatively rare. It exists in two molecular forms: coagulant activity may be reduced together with factor V antigen levels (impaired synthesis), or low coagulant activity is associated with the presence of a variable level of plasma factor V (abnormal molecules). Both conditions lead to frequent minor bleedings of skin and mucosal tissues. Acquired deficiency with reduced factor V antigen levels can be a reliable parameter of liver damage in severe liver diseases. Circulating antibodies to factor V acting as neutralizing inhibitors of plasma an platelet factor V have been described. Highly purified Factor V is isolated from pooled human plasma and used for immunization. Freund?s complete adjuvant is used in the first step of the immunization procedure.

Precipitating polyclonal Rabbit antiSerum to Human coagulation factor V.

P12259